Advertisement

Compounding Pharmacies Come Under Scrutiny in Light of Meningitis Outbreak — Physician’s First Watch

Medical News |
October 12, 2012

Compounding Pharmacies Come Under Scrutiny in Light of Meningitis Outbreak

Compounding pharmacies are getting widespread attention in the midst of the fungal meningitis outbreak that has affected at least 170 patients and claimed 14 lives. The outbreak has been linked to methylprednisolone acetate injections distributed by the New England Compounding Center (NECC) in Massachusetts.

Compounding pharmacies are not regulated by the FDA but rather "are subject to a patchwork of state oversight," Reuters notes. A second compounding pharmacy in Massachusetts, Ameridose, temporarily closed pending an inspection by state officials. NECC and Ameridose share an owner.

In other outbreak-related news, the CDC says that 10 of the meningitis patients have tested positive for the fungus Exserohilum and 1 for Aspergillus.

In Tennessee, the hardest hit state, health officials estimate that 5% of patients who received the implicated injections from NECC have contracted meningitis.

Your Comment

(will not be published)

Filtered HTML

  • Allowed HTML tags: <a> <em> <strong> <cite> <blockquote> <code> <ul> <ol> <li> <dl> <dt> <dd>
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Do you have any conflict of interest to disclose?
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.
Image CAPTCHA
Enter the characters shown in the image.

Vertical Tabs

* Required

Reader comments are intended to encourage lively discussion of clinical topics with your peers in the medical community. We ask that you keep your remarks to a reasonable length, and we reserve the right to withhold publication of remarks that do not meet this standard.

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.

Advertisement
Advertisement
Advertisement